The UAE research community moved quickly on GLP-1 receptor agonist peptides — and retatrutide is the molecule that justified the speed. While semaglutide and tirzepatide operate on one or two receptors, retatrutide simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. That triple-agonism is not a marketing formulation — it produced a metabolic profile in Phase 2 trials that has reshaped what investigators benchmark against. If you are looking to buy retatrutide UAE for a legitimate research protocol, this guide covers what the clinical literature actually shows, how to structure a titration model based on published escalation schemes, and how to get REVIVE LAB UAE cold-chain vials at your door — cash on delivery — whether you are based in Dubai, Abu Dhabi, Sharjah or any other emirate.
Most peptide researchers in the UAE are already comfortable with the GLP-1 axis: receptor activation slows gastric emptying, suppresses appetite via hypothalamic circuits, and drives insulin secretion in a glucose-dependent fashion. Retatrutide does all of that — and adds two more levers.
This is the pharmacological rationale behind the Phase 2 findings. Understanding it is also the first step to understanding why the titration protocol matters so much — and why stocked vial sizes need to accommodate a genuine escalation model, not a single flat dose.
Two landmark publications define the evidence base investigators cite when designing retatrutide research protocols in 2026.
The Jastreboff 2023 study published in the New England Journal of Medicine enrolled 338 adults with obesity (BMI ≥30) or overweight with a weight-related comorbidity, randomised to once-weekly subcutaneous retatrutide at escalating doses versus placebo, over 48 weeks. Key findings from the published data:
Rosenstock and colleagues published in The Lancet a parallel Phase 2 evaluation of retatrutide in adults with type 2 diabetes. Across 36 weeks, once-weekly retatrutide produced reductions in HbA1c of up to −2.02 percentage points from baseline versus placebo, alongside body weight reductions that were substantial even within the shorter 36-week observation window. The Lancet data confirmed that the triple-agonist mechanism translated to meaningful glycaemic control independent of the obesity indication studied in Jastreboff — broadening the investigator use-case considerably.
Taken together, the Jastreboff 2023 NEJM data and Rosenstock 2023 Lancet data establish retatrutide as the highest-signal incretin-class research compound currently available. For investigators looking to order retatrutide in the UAE, these two trials are the papers your protocol review will reference.
REVIVE LAB UAE supplies retatrutide in two lyophilized vial strengths: 5mg and 10mg. Both are HPLC-verified, shipped with lot-level COA documentation, and dispatched cold-chain. No other strengths are stocked. Investigators designing protocols should build their titration model around these two sizes.
The published escalation scheme from the Jastreboff 2023 NEJM trial used a stepped weekly dose increase, beginning at a low starting dose to manage GI tolerability and ramping through mid-range doses over several weeks. The following table maps the published research-context escalation to REVIVE LAB UAE vial sizes for investigator reference.
| Research Phase | Weekly Dose (Research-Context) | Vial Strategy | Tolerance Checkpoint |
|---|---|---|---|
| Weeks 1-4 (initiation) | 2mg | 5mg vial ÷ 2.5 aliquots | GI tolerability — confirm before escalation |
| Weeks 5-8 (escalation) | 4mg | 5mg vial ÷ 1.25 aliquots | Appetite suppression onset, GI normalising |
| Weeks 9+ (maintenance) | 8mg | 10mg vial ÷ 1.25 aliquots | Full metabolic activation; weekly weigh-in protocol |
Note: the 2mg → 4mg → 8mg titration ladder is derived from the published Phase 2 escalation methodology. It is provided here as a research reference. REVIVE LAB UAE does not prescribe dosing schedules — this information is for investigators reviewing the Jastreboff 2023 NEJM protocol.
| Vial Size | BAC Water | Concentration | Volume per 2mg Research Dose |
|---|---|---|---|
| Retatrutide 5mg | 1 mL | 5 mg/mL | 0.40 mL |
| Retatrutide 5mg | 2 mL | 2.5 mg/mL | 0.80 mL |
| Retatrutide 10mg | 2 mL | 5 mg/mL | 0.40 mL per 2mg / 0.80 mL per 4mg / 1.60 mL per 8mg |
| Retatrutide 10mg | 4 mL | 2.5 mg/mL | 0.80 mL per 2mg / 1.60 mL per 4mg |
For researchers across the UAE who prefer not to transact online before verifying product receipt, cash on delivery is the default payment method at REVIVE LAB UAE. The process is straightforward and does not require advance card authorisation or wire transfer.
| Emirate / Key Areas | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm, Jumeirah, Emirates Hills, Arabian Ranches) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas Island, Saadiyat, Reem Island, Khalidiyah) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18-24 hours | Yes | Yes |
Researchers in Dubai placing orders before the daily cut-off can expect retatrutide Dubai 24h delivery — in many cases same-day, 4-8 hours for central Dubai districts. This is what a genuinely UAE-based peptides operation looks like versus an offshore catalogue that relabels and forwards from a third country.
For investigators who prefer digital settlement, REVIVE LAB UAE also accepts USDT via TRC20 (Binance Pay compatible). Orders paid in USDT upfront receive a 5% discount off the standard price — confirm via WhatsApp and share your transaction ID after payment. This is the preferred route for researchers ordering in volume or managing recurring protocol supply. Cash on delivery Dubai remains available as the default for those who prefer it.
The UAE peptides market has matured rapidly since 2024, and so has the gap between suppliers who genuinely hold stock and those who appear to. For researchers sourcing retatrutide, these are the verifiable differentiators REVIVE LAB UAE provides:
For investigators also running tesamorelin (GHRH analog), GHK-Cu (copper tripeptide), BPC-157, TB-500 or other peptides UAE protocols alongside retatrutide, REVIVE LAB UAE stocks the full research stack. Ask for a combined order to simplify cold-chain delivery logistics.
Yes. Cash on delivery Dubai and across all seven emirates is the default payment method at REVIVE LAB UAE. You do not pay until the courier arrives with your cold-chain packed retatrutide vials. USDT crypto pay via TRC20 is also available with a 5% pre-pay discount for researchers who prefer it.
REVIVE LAB UAE stocks retatrutide 5mg and 10mg lyophilized vials — no other strengths. The research-context titration referenced in the Jastreboff 2023 NEJM TRIPLE-PHARMACOLOGY trial follows a 2mg → 4mg → 8mg weekly escalation. The 5mg vial covers the 2mg and 4mg initiation phases; the 10mg vial supports the 8mg maintenance phase efficiently. Most investigators running a 48-week protocol will use both sizes at different stages.
For researchers in Dubai, orders placed before the daily dispatch cut-off arrive same-day — typical window 4-8 hours to Dubai Marina, JBR, Business Bay, JVC, DIFC, Downtown Dubai, Palm Jumeirah, Jumeirah, Emirates Hills and Arabian Ranches. This is genuine retatrutide Dubai 24h delivery from local stock, not a drop-ship ETA from a third country. For Abu Dhabi, Sharjah, Ajman, RAK, Fujairah and Umm Al Quwain: next-day, 18-24 hours, cold-chain maintained throughout.